OLN324: Why Size May Matter - Summary - MDSpire

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

  • By

  • David A. Eichenbaum, MD

  • Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

  • 3 min

Share

Objective:

To discuss the phase 1 JADE study findings comparing OLN324 to faricimab in treating nAMD and diabetic macular edema.

Approach:
  • Study Design: The study involved 4 doses of OLN324 (high dose 4 mg, low dose 2 mg) administered monthly, compared to faricimab, with a primary endpoint at week 12 and study completion at week 20.
Key Findings:
  • In diabetic macular edema (DME), OLN324 showed better and deeper retinal drying compared to faricimab, with 50% more patients achieving DME resolution at week 12.
  • In age-related macular degeneration (AMD), OLN324 demonstrated a gain of 2.2 letters in visual acuity compared to faricimab and more significant flattening of pigment epithelial detachments (PEDs).
  • OLN324's small format (41 kDa) allows for high binding affinity and molarity.
Interpretation:

Conclusion:

Further phase 3 studies are anticipated to validate these findings.

Original Source(s)

OLN324: Why Size May Matter

  • by David A. Eichenbaum, MD, Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

Related Content

Malpositioned orbital implants: indications for implant removal and secondary reconstructive techniques

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

Amniotic Dressing Shows NHS Promise

UK NHS study finds clinic-based treatment may help corneal wounds heal sooner

  • July 21, 2026

  • 3 min